{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T06:08:59Z","timestamp":1777356539242,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Infectious Diseases"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/s1473-3099(06)70552-7","type":"journal-article","created":{"date-parts":[[2006,7,25]],"date-time":"2006-07-25T07:55:22Z","timestamp":1153814122000},"page":"522-528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design"],"prefix":"10.1016","volume":"6","author":[{"given":"Hannah B","family":"Ibanga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger H","family":"Brookes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip C","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick K","family":"Owiafe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen A","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Lienhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian VS","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A","family":"Adegbola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"McShane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S1473-3099(06)70552-7_bib1","series-title":"TB, a global emergency","year":"1994"},{"key":"10.1016\/S1473-3099(06)70552-7_bib3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.282.7.677","article-title":"Global burden of tuberculosis","volume":"282","author":"Dye","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/S1473-3099(06)70552-7_bib4","series-title":"Issues relating to the use of BCG in immunisation programmes","author":"Fine","year":"1999"},{"key":"10.1016\/S1473-3099(06)70552-7_bib5","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/ije\/22.6.1154","article-title":"Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis","volume":"22","author":"Rodrigues","year":"1993","journal-title":"Int J Epidemiol"},{"issue":"suppl 2","key":"10.1016\/S1473-3099(06)70552-7_bib6","doi-asserted-by":"crossref","first-page":"S353","DOI":"10.1093\/clinids\/11.Supplement_2.S353","article-title":"The BCG story: lessons from the past and implications for the future","volume":"11","author":"Fine","year":"1989","journal-title":"Rev Infect Dis"},{"key":"10.1016\/S1473-3099(06)70552-7_bib7","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S0140-6736(05)67145-0","article-title":"Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial","volume":"366","author":"Rodrigues","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/S1473-3099(06)70552-7_bib8","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(02)08353-8","article-title":"BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies","volume":"359","author":"Black","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/S1473-3099(06)70552-7_bib9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/IAI.70.2.672-678.2002","article-title":"Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis","volume":"70","author":"Brandt","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/S1473-3099(06)70552-7_bib10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S1473-3099(02)00182-2","article-title":"BCG\u2014different strains, different vaccines?","volume":"2","author":"Behr","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/S1473-3099(06)70552-7_bib11","first-page":"553","article-title":"Long term results of BCG vaccination in the southern United States","volume":"94","author":"Comstock","year":"1966","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/S1473-3099(06)70552-7_bib12","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/0140-6736(90)93087-6","article-title":"BCG vaccination and nutrition","volume":"335","author":"Epstein","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/S1473-3099(06)70552-7_bib13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev.immunol.19.1.93","article-title":"Immunology of tuberculosis","volume":"19","author":"Flynn","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/S1473-3099(06)70552-7_bib14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/35095558","article-title":"How can immunology contribute to the control of tuberculosis?","volume":"1","author":"Kaufmann","year":"2001","journal-title":"Nat Rev Immunol"},{"issue":"suppl 3","key":"10.1016\/S1473-3099(06)70552-7_bib15","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.1086\/313874","article-title":"Correlates of protective immunity to Mycobacterium tuberculosis in humans","volume":"30","author":"Ellner","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S1473-3099(06)70552-7_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.tube.2004.09.015","article-title":"Boosting BCG with MVA85A, the first candidate subunit vaccine for tuberculosis in clinical trials","volume":"85","author":"McShane","year":"2005","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/S1473-3099(06)70552-7_bib17","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nm1128","article-title":"Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG primed and naturally acquired anti-mycobacterial immunity in humans","volume":"10","author":"McShane","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/S1473-3099(06)70552-7_bib18","doi-asserted-by":"crossref","first-page":"13853","DOI":"10.1073\/pnas.250480397","article-title":"Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model","volume":"97","author":"Horwitz","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S1473-3099(06)70552-7_bib19","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.micinf.2005.04.002","article-title":"Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins","volume":"7","author":"Horwitz","year":"2005","journal-title":"Microbes Infect"},{"key":"10.1016\/S1473-3099(06)70552-7_bib20","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.4049\/jimmunol.172.12.7618","article-title":"Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein","volume":"172","author":"Skeiky","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/S1473-3099(06)70552-7_bib22","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrmicro1419","article-title":"Advances in tuberculosis vaccine strategies","volume":"4","author":"Skeiky","year":"2006","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/S1473-3099(06)70552-7_bib23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S1473-3099(05)01290-9","article-title":"Tuberculosis vaccine trials","volume":"5","author":"von Reyn","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/S1473-3099(06)70552-7_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0041-3879(91)90019-O","article-title":"Cytokines and the Koch phenomenon","volume":"72","author":"Rook","year":"1991","journal-title":"Tubercle"},{"key":"10.1016\/S1473-3099(06)70552-7_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1055\/s-0029-1206198","article-title":"Fortstzung \u00fcber ein Heilmittel gegen Tuberculose","volume":"17","author":"Koch","year":"1891","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/S1473-3099(06)70552-7_bib26","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1128\/IAI.71.4.2192-2198.2003","article-title":"Pulmonary necrosis resulting from DNA vaccination against tuberculosis","volume":"71","author":"Taylor","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/S1473-3099(06)70552-7_bib27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1128\/IAI.72.1.381-388.2004","article-title":"Immune responses to mycobacterial antigens in the Gambian population: implications for vaccines and immunodiagnostic test design","volume":"72","author":"Vekemans","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/S1473-3099(06)70552-7_bib28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/427030","article-title":"Quantitative T cell assay reflects infectious load of Mycobacterium tuberculosis in an endemic case contact model","volume":"40","author":"Hill","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S1473-3099(06)70552-7_bib29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1086\/338149","article-title":"Evolution and current use of the tuberculin test","volume":"34","author":"Lee","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S1473-3099(06)70552-7_bib30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0196-6553(95)90039-X","article-title":"Tuberculin skin test conversion in hospital employees vaccinated with bacille Calmette-Guerin: recent Mycobacterium tuberculosis infection or booster effect?","volume":"23","author":"Horowitz","year":"1995","journal-title":"Am J Infect Control"},{"key":"10.1016\/S1473-3099(06)70552-7_bib31","first-page":"213","article-title":"Epidemiologic studies of tuberculin sensitivity, I: preliminary results with purified protein derivatives prepared from atypical acid fast organism","volume":"66","author":"Edwards","year":"1958","journal-title":"Am J Hyg"},{"key":"10.1016\/S1473-3099(06)70552-7_bib32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.7326\/0003-4819-119-3-199308010-00002","article-title":"Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Pulmonary Complications of HIV Infection Study Group","volume":"119","author":"Markowitz","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/S1473-3099(06)70552-7_bib33","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1164\/rccm.200212-1483OC","article-title":"Risk factors for tuberculosis infection in sub-Saharan Africa: a contact study in The Gambia","volume":"168","author":"Lienhardt","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/S1473-3099(06)70552-7_bib34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1473-3099(04)01206-X","article-title":"Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review","volume":"4","author":"Pai","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/S1473-3099(06)70552-7_bib35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1164\/rccm.2404004","article-title":"Diagnosing latent tuberculosis infection: turning glitter to gold","volume":"170","author":"Barnes","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/S1473-3099(06)70552-7_bib36","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1128\/iai.63.5.1710-1717.1995","article-title":"Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis","volume":"63","author":"Sorensen","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/S1473-3099(06)70552-7_bib37","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/iai.64.1.16-22.1996","article-title":"Evidence for occurence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG","volume":"64","author":"Harboe","year":"1996","journal-title":"Infect Immun"},{"key":"10.1016\/S1473-3099(06)70552-7_bib38","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1086\/593686","article-title":"The potential of the ESAT-6 antigen secreted by virulent mycobacteria for specific diagnosis of tuberculosis","volume":"175","author":"Pollock","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/S1473-3099(06)70552-7_bib39","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1084\/jem.186.6.859","article-title":"Rapid effector function in CD8+ memory T cells","volume":"186","author":"Lalvani","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/S1473-3099(06)70552-7_bib40","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1086\/382362","article-title":"Large-scale evaluation enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia","volume":"38","author":"Hill","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S1473-3099(06)70552-7_bib41","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/adc.59.7.614","article-title":"Tuberculin response two years after BCG vaccination at birth","volume":"59","author":"Grindulis","year":"1984","journal-title":"Arch Dis Child"},{"key":"10.1016\/S1473-3099(06)70552-7_bib42","first-page":"1133","article-title":"BCG scars in northern Malawi: sensitivity and repeatability of scar reading, and factors affecting size","volume":"4","author":"Floyd","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/S1473-3099(06)70552-7_bib43","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1097\/00002030-200308150-00014","article-title":"Regional differences in HIV trends in The Gambia: results from sentinel surveillance among pregnant women","volume":"17","author":"Schim van der Loeff","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/S1473-3099(06)70552-7_bib44","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/0035-9203(95)90005-5","article-title":"Recruitment to a trial of tuberculosis preventive therapy from a voluntary HIV testing centre in Lusaka: relevance to implementation","volume":"89","author":"Godfrey-Faussett","year":"1995","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/S1473-3099(06)70552-7_bib45","series-title":"The Belmont report. OPRR Reports","year":"1988"},{"key":"10.1016\/S1473-3099(06)70552-7_bib46","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0140-6736(05)66992-9","article-title":"Undue inducement in clinical research in developing countries: is it a worry?","volume":"366","author":"Emanuel","year":"2005","journal-title":"Lancet"}],"container-title":["The Lancet Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473309906705527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473309906705527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T09:04:20Z","timestamp":1761469460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473309906705527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S1473309906705527"],"URL":"https:\/\/doi.org\/10.1016\/s1473-3099(06)70552-7","relation":{},"ISSN":["1473-3099"],"issn-type":[{"value":"1473-3099","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design","name":"articletitle","label":"Article Title"},{"value":"The Lancet Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1473-3099(06)70552-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}